The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...

Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

In this May 4, 2014 photo, the Pfizer logo is displayed on the exterior of a former Pfizer factory in the Brooklyn borough of New York. (AP Photo/Mark Lennihan, File) Updated at 10:58 a.m. NEW YORK • ...

Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...

Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...